161 related articles for article (PubMed ID: 22427410)
1. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis.
Baraliakos X; van den Berg R; Braun J; van der Heijde D
Rheumatology (Oxford); 2012 Aug; 51(8):1378-87. PubMed ID: 22427410
[TBL] [Abstract][Full Text] [Related]
2. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.
Braun J; Davis J; Dougados M; Sieper J; van der Linden S; van der Heijde D;
Ann Rheum Dis; 2006 Mar; 65(3):316-20. PubMed ID: 16096329
[TBL] [Abstract][Full Text] [Related]
3. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.
van der Heijde D; Sieper J; Maksymowych WP; Dougados M; Burgos-Vargas R; Landewé R; Rudwaleit M; Braun J;
Ann Rheum Dis; 2011 Jun; 70(6):905-8. PubMed ID: 21540200
[TBL] [Abstract][Full Text] [Related]
4. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
Braun J; Baraliakos X; Listing J; Sieper J
Arthritis Rheum; 2005 Aug; 52(8):2447-51. PubMed ID: 16052578
[TBL] [Abstract][Full Text] [Related]
5. ASAS/EULAR recommendations for the management of ankylosing spondylitis.
Zochling J; van der Heijde D; Burgos-Vargas R; Collantes E; Davis JC; Dijkmans B; Dougados M; Géher P; Inman RD; Khan MA; Kvien TK; Leirisalo-Repo M; Olivieri I; Pavelka K; Sieper J; Stucki G; Sturrock RD; van der Linden S; Wendling D; Böhm H; van Royen BJ; Braun J; ;
Ann Rheum Dis; 2006 Apr; 65(4):442-52. PubMed ID: 16126791
[TBL] [Abstract][Full Text] [Related]
6. First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.
van den Berg R; Baraliakos X; Braun J; van der Heijde D
Rheumatology (Oxford); 2012 Aug; 51(8):1388-96. PubMed ID: 22513148
[TBL] [Abstract][Full Text] [Related]
7. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
[TBL] [Abstract][Full Text] [Related]
8. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
[TBL] [Abstract][Full Text] [Related]
10. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome.
Baraliakos X; Listing J; Fritz C; Haibel H; Alten R; Burmester GR; Krause A; Schewe S; Schneider M; Sörensen H; Schmidt R; Sieper J; Braun J
Rheumatology (Oxford); 2011 Sep; 50(9):1690-9. PubMed ID: 21672969
[TBL] [Abstract][Full Text] [Related]
11. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Wang S; He Q; Shuai Z
Clin Rheumatol; 2018 Feb; 37(2):439-450. PubMed ID: 29290076
[TBL] [Abstract][Full Text] [Related]
12. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
13. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists].
Brandt J; Sieper J; Braun J
Z Rheumatol; 2003 Jun; 62(3):218-27. PubMed ID: 12827397
[TBL] [Abstract][Full Text] [Related]
15. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
[TBL] [Abstract][Full Text] [Related]
16. Infliximab treatment in ankylosing spondylitis: an observational study.
Nikas SN; Alamanos Y; Voulgari PV; Pliakou XI; Papadopoulos CG; Drosos AA
Ann Rheum Dis; 2005 Jun; 64(6):940-2. PubMed ID: 15564309
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
Calin A; Dijkmans BA; Emery P; Hakala M; Kalden J; Leirisalo-Repo M; Mola EM; Salvarani C; Sanmartí R; Sany J; Sibilia J; Sieper J; van der Linden S; Veys E; Appel AM; Fatenejad S
Ann Rheum Dis; 2004 Dec; 63(12):1594-600. PubMed ID: 15345498
[TBL] [Abstract][Full Text] [Related]
18. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.
Maksymowych WP; Inman RD; Gladman D; Thomson G; Stone M; Karsh J; Russell AS;
J Rheumatol; 2003 Jun; 30(6):1356-63. PubMed ID: 12784417
[TBL] [Abstract][Full Text] [Related]
19. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
Baraliakos X; Brandt J; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
Arthritis Rheum; 2005 Dec; 53(6):856-63. PubMed ID: 16342093
[TBL] [Abstract][Full Text] [Related]
20. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J
Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
